News

Emerging acne therapies like narrow-spectrum antibiotics, hormonal agents, and immunomodulators are promising, more personalized alternatives to isotretinoin, according to new research.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss phase 3 data presented at AAD showing patients moving from very severe disease at baseline to absent or mild disease by week 40.

Around 80% of clinical trials face enrollment delays, and for rare genodermatoses with small patient pools, AI-generated synthetic control arms may offer a practical path to adequately powered studies.

Patients who are needle-averse may soon have effective non-injectable options with biologic-like results.

At AAD 2026, Diego Ruiz Dasilva, MD, makes the case that the black box warning on JAK inhibitors shouldn't deter appropriate prescribing.

A new review examined the bone–vascular axis in psoriasis and how the current therapeutic toolbox can influence cardiovascular and skeletal health.

The inaugural DermVIP Summit will be held from May 8 to 9 at the New York Academy of Medicine.

Steven Daveluy, MD, discusses how this approval helps close a critical gap in care for adolescents living with HS.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on phase 3 AD SHORE trials for amlitelimab, the expansion of coverage for tirbanibulin, the start of a phase 2b/3 of brepocitinib for LPP, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Hope Mitchell, MD, shared practical strategies for protecting and cultivating an online presence at the 2026 American Academy of Dermatology Annual Meeting.

Mark Jackson, MD, of Evommune, provides a therapeutic update on the investigational atopic dermatitis drug, citing strong efficacy and safety after just 2 doses, with phase 2b research on the way.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Mohammad Jafferany, MD, discuss how integrating mental health and dermatologic care can improve outcomes for patients with chronic skin conditions.

AAD honors Henry W. Lim, MD, FAAD, with the Academy's highest honor for his work in photodermatology advances, skin of color care, and global leadership.

Offers must pair strong compensation with operational and cultural support to succeed.

Steven Daveluy, MD, reviews long-term trial data for bimekizumab in psoriasis and hidradenitis suppurativa presented at the 2026 AAD Annual Meeting.

Explore top dermatology conferences and meetings in April 2026 and let us know which ones you'll be attending!

Kimball presented new data on MoonLake Immunotherapeutics’ sonelokimab and reflected on other HS updates presented at AAD 2026.

Hoth Therapeutics has received regulatory approval in Hungary to expand the phase 2 trial into Europe, with Spain and Poland approvals anticipated.

LPP affects roughly 100,000 adults in the US and currently has no FDA-approved treatments.

Daniel C. Butler, MD, discusses the underrepresentation of older adults in dermatology trials and what a 3-system framework for itch means for clinical practice

The ongoing phase 2b BROADEN2 study will evaluate KT-621 across 3 dose levels in 200 patients over 16 weeks, with results expected to guide phase 3 dose selection.

Christopher Bunick, MD, PhD, and Almirall's Johnny Im discuss new data showing that tirbanibulin 1% ointment provides consistent efficacy, while expanded coverage is poised to improve patient access in the US.

The combination therapy SHORE trial produced the highest response rates of the 3 studies, with EASI-75 approaching 48% in the Q4W arm.

Liza O'Dowd, MD, discusses the drug's long road to FDA approval and what its oral delivery means for patients with plaque psoriasis.

Dermatology Times is looking back on the top stories in dermatology from the month of March.

The trial’s results may support earlier use of dual IL-17A/F inhibitors in patients with both skin and joint disease.